Evidence map›Paper›PMID 40132120›Full record

ArticleBlood2025

Tracking clusterin expression in hematopoietic stem cells reveals their heterogeneous composition across the life span.

Shuhei Koide, Motohiko Oshima, Takahiro Kamiya, Zhiqian Zheng, Zhaoyi Liu, Ola Rizq, Akira Nishiyama, Koichi Murakami, Yuta Yamada, Yaeko Nakajima-Takagi and 11 more

Abstract read
In one paragraph

Article in Blood, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Improving lymphopoiesis in aged bone marrow.Current opinion in hematology · 2026
    Review
  4. The systemic costs of hematopoietic stem cell aging.Development (Cambridge, England) · 2025
    Review
  5. Article
  6. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Shuhei KoideDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Motohiko OshimaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Takahiro KamiyaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0003-3080-3747
Zhiqian ZhengDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0009-0007-3723-9727
Zhaoyi LiuDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Ola RizqDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Akira NishiyamaDepartment of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID 0000-0002-8802-3770
Koichi MurakamiDepartment of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yuta YamadaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Yaeko Nakajima-TakagiDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Bahityar RahmutullaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Atsushi KanedaDepartment of Molecular Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
Kazuaki YokoyamaDepartment of Hematology/Oncology, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0002-2556-3833
Nozomi YusaDepartment of Laboratory Medicine, Research Hospital, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0009-0000-7801-0549
Seiya ImotoDivision of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
Fumihito MiuraDepartment of Biochemistry, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.ORCID 0000-0003-2656-486X
Takashi ItoDepartment of Biochemistry, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan.ORCID 0000-0001-6097-2803
Tomohiko TamuraDepartment of Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.ORCID 0000-0002-9664-1747
Claus NerlovMedical Research Council (MRC) Molecular Haematology Unit, MRC Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Masayuki YamashitaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9459-4329
Atsushi IwamaDivision of Stem Cell and Molecular Medicine, Center for Stem Cell Biology and Regenerative Medicine, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID 0000-0001-9410-8992

Funding

Basic and Translational Research Training in Pediatric Classical HematologyT32HL176447 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI SHANNON L MCKINNEY-FREEMAN · 2025 to 2026
$505k
NHLBI NIH HHS T32 HL176447
6 · The paper itself

Abstract

abstractHematopoietic stem cells (HSCs) exhibit significant age-related phenotypic and functional alterations. Although single-cell technologies have elucidated age-related compositional changes, prospective identification of aging-associated HSC subsets has remained challenging. In this study, using clusterin (Clu)-green fluorescent protein (GFP) reporter mice, we demonstrated that Clu expression faithfully marks age-associated myeloid/platelet-biased HSCs throughout life. Clu-GFP expression clearly segregates a novel age-associated HSC subset that overlaps with but is distinct from those previously identified using antibodies against aging maker proteins or reporter systems of aged HSC signature genes. Clu-positive (Clu+) HSCs emerge as a minor population in the fetus and progressively expand with age. Clu+ HSCs display not only an increased propensity for myeloid/platelet-biased differentiation but also a unique behavior in the bone marrow, favoring self-renewal over differentiation into downstream progenitors. In contrast, Clu-negative (Clu-) HSCs exhibit lineage-balanced differentiation, which predominates in the HSC pool during development but becomes underrepresented as aging progresses. Both subsets maintain long-term self-renewal capabilities even in aged mice but contribute differently to hematopoiesis. The predominant expansion of Clu+ HSCs largely drives the age-related changes observed in the HSC pool. Conversely, Clu- HSCs preserve youthful functionality and molecular characteristics into old age. Consequently, progressive changes in the balance between Clu+ and Clu- HSC subsets account for HSC aging. Our findings establish Clu as a novel marker for identifying aging-associated changes in HSCs and provide a new approach that enables lifelong tracking of the HSC aging process.

Indexed as

AgingClusterinHematopoietic Stem CellsAnimalsCell DifferentiationCellular SenescenceGreen Fluorescent ProteinsHematopoiesisMiceMice, Inbred C57BLMice, TransgenicClu protein, mouseClusterinGreen Fluorescent Proteins

Identifiers

PMID40132120
PMCPMC12883850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.